ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025
Use of fatigue assessment scale and small fiber neuropathy screening list in Japanese patients with sarcoidosis.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Quality of Life in Sarcoidosis.Diagnostics (Basel, Switzerland) · 2026Review
- Assessment of Disease Burden Among Japanese Patients With Pulmonary Sarcoidosis: A Questionnaire-Based Study.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Fatigue Assessment Scale (FAS) and Small Fiber Neuropathy Screening List (SFNSL) are widely used in Western countries to investigate symptoms associated with fatigue and small fiber neuropathy (SFN). However, few studies have used these patient-reported outcome measures (PROMs) in Japan.
methodsThis was a cross-sectional and longitudinal study at an outpatient clinic in a community teaching hospital in Japan. Participants completed the FAS, SFNSL, and Short Form-36. Clinical parameters, including angiotensin-converting enzyme (ACE) and soluble interleukin-2 receptor (sIL2R), were derived from the medical records of the patients.
resultsThe study population included 55 patients (29 males; 26 females; mean age: 59±15 years; median disease duration: 5.0 years). Eleven patients received a systemic corticosteroid. The mean FAS score was 22.7±8.2; 27 patients (49.1%) and five patients (9.1%) indicated fatigue (score: ≥22) and extreme fatigue (score: ≥35), respectively. The mean SFNSL score was 13.8±14.3; 23 patients (41.8%) and two patients (3.6%) indicated probable/highly probable SFN (score: 11-48) and SFN (score: ≥49), respectively. The FAS score exhibited strong correlations with physical function, vitality, and mental health of Short Form-36. The SFNSL score exhibited strong correlations with bodily pain and vitality. Of the 55 patients, 45 completed the 1-year follow-up. There were no significant changes noted in the FAS score (mean: 0.04, 95% confidence interval: -1.29-1.38) and SFNSL score (mean: 0.31, 95% confidence interval: -2.12-2.74) during the follow-up. Within-subject changes in FAS and SFNSL scores showed moderate correlations with those of physical function and general health, respectively. There was no significant relationship between FAS or SFNSL score and ACE or sIL2R values at baseline and within-subject changes in these parameters during the follow-up.
conclusionsApproximately half of the patients suffered from fatigue or SFN. These nonspecific symptoms have a great effect on quality of life.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.